Secondary hyperparathyroidism

Treatment Phase: Continuing treatment

Treatment criteria:

• Must be treated by a nephrologist.

Clinical criteria:

• Patient must have chronic kidney disease,

AND

• Patient must be on dialysis,

AND

• Patient must have previously received PBS-subsidised treatment with this drug for this condition.

During the maintenance phase, iPTH should be monitored quarterly (measured at least 12 hours post dose) and dose adjusted as necessary to maintain an appropriate iPTH concentration.

During the maintenance phase, prescribers should request approval to allow sufficient supply for 4 weeks treatment up to a maximum of 6 months supply, with doses between 30 and 180 mg per day according to the patient's response and tolerability.